NeuroPace, Inc. (NASDAQ:NPCE - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for NeuroPace in a research report issued to clients and investors on Thursday, April 3rd. Leerink Partnrs analyst M. Kratky forecasts that the company will earn ($0.24) per share for the quarter. The consensus estimate for NeuroPace's current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace's Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at $0.59 EPS.
Several other analysts have also recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. raised their price objective on NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Cantor Fitzgerald boosted their target price on NeuroPace from $19.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, UBS Group began coverage on NeuroPace in a report on Tuesday, January 21st. They set a "buy" rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.20.
Check Out Our Latest Stock Analysis on NeuroPace
NeuroPace Price Performance
NPCE stock traded down $0.22 during trading on Monday, hitting $10.42. 102,130 shares of the company's stock traded hands, compared to its average volume of 130,033. NeuroPace has a 52 week low of $5.45 and a 52 week high of $15.11. The stock has a market capitalization of $339.28 million, a price-to-earnings ratio of -10.42 and a beta of 2.03. The business has a fifty day simple moving average of $12.17 and a 200 day simple moving average of $10.61. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59.
NeuroPace (NASDAQ:NPCE - Get Free Report) last posted its earnings results on Tuesday, March 4th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. The firm had revenue of $21.47 million during the quarter, compared to the consensus estimate of $21.14 million.
Insider Buying and Selling
In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Martha Morrell sold 78,334 shares of the stock in a transaction on Friday, February 21st. The stock was sold at an average price of $13.72, for a total value of $1,074,742.48. Following the completion of the sale, the insider now owns 81,993 shares in the company, valued at approximately $1,124,943.96. The trade was a 48.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,352,479 shares of company stock valued at $50,670,217 in the last ninety days. 22.20% of the stock is owned by company insiders.
Institutional Investors Weigh In On NeuroPace
Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets bought a new stake in shares of NeuroPace during the fourth quarter valued at approximately $29,000. GAMMA Investing LLC bought a new stake in NeuroPace during the 1st quarter valued at $53,000. Wells Fargo & Company MN lifted its holdings in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after buying an additional 2,279 shares during the period. MetLife Investment Management LLC bought a new position in shares of NeuroPace during the 4th quarter worth $103,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of NeuroPace during the 4th quarter worth $112,000. 78.83% of the stock is owned by hedge funds and other institutional investors.
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
